Skip to Main Content awarded nearly $3.5 million in federal funding


2 mins

New development will combine multimodal imaging technology with other patient data to predict cancer diagnoses and guide clinical decision-making


(SAN DIEGO) Nov. 17, 2021 — today announced its receipt of two federal awards that will fund the development of advanced AI tools to be used to help predict and manage care of clinically significant prostate and brain cancer. The nearly $3.5 million in total of non-dilutive funding will be released over a two-and-a-half-year period.  Federal awarding agencies of the National Institute of Health (NIH) include the National Cancer Institute (NCI) and the National Institute of Neurological Disorders and Stroke. proposes more advanced imaging and integrated models to address the lack of accurate clinical decision support tools for cancer prediction, detection, and treatment selection. Its applications were titled, RSI-AI: Predicting clinically significant prostate cancer to guide biopsy decisions by combining advanced tissue microstructure imaging with deep learning” and “Towards a Virtual Biopsy: An improved multimodal imaging biomarker to guide treatment decisions in neuro-oncology by combining advanced tissue microstructure imaging with deep learning.” These new AI developments will leverage and build upon’s existing FDA-cleared applications in prostate and neuro-imaging, to combine these with other clinical data that may include genetics, liquid biomarkers, etc., for more actionable insights. 

“With these grants, we hope to contribute to the medical field’s goal of early detection and precision diagnostics and treatment for cancer,” says Nate White PhD, chief technology officer at and co-inventor of the Restriction Spectrum Imaging (RSI) for oncologic imaging. “Better risk stratification and patient selection for biopsy and intervention will shorten the time and cost to get to accurate diagnoses and proper treatment,” White added. The goal is to continue to build, optimize, and expand these solutions for cancers outside of the prostate and brain, as well as other applicable diseases where this is a clinical need. has been a market leader in radiology AI since the debut of their flagship product NeuroQuant® in 2007. Their acquisition of HealthLytix in 2020 was the first step in establishing market presence in both the prostate imaging and oncology space. “These grants give the opportunity to broaden its natural evolution as a leader in radiology AI and beyond, to deliver insights that directly impact clinical decision making of entire care teams,” says Chris Airriess PhD, chief executive officer. The company’s application included letters of support from executives at GE Healthcare and Siemens Healthineers, members of the PI-RADS Steering Committee, and other experts from multiple departments including radiology, urology, neurology, and radiation oncology. 

About is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, healthier lives. The company develops and markets breakthrough medical device software that quantifies and tracks neurodegenerative diseases and assists in the detection of clinically significant cancer.’s industry-leading brain imaging analysis provides radiologists, neurologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis and follow up of neurodegenerative and traumatic brain conditions, as well as prostate cancer. Please visit for further information and follow us on Twitter, LinkedIn, and Facebook.


Contact: Josh Cohen

Phone: +1 (858) 459-9702